![Carlo Incerti](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Carlo Incerti
Directeur/Membre du Conseil chez
DYNE THERAPEUTICS, INC.
Fortune : - $ au 30/06/2026
Profil
Carlo Incerti is currently Chairman at Azafaros BV since 2020, Director at Numab Therapeutics AG since 2021, Independent Director at Dyne Therapeutics, Inc. since 2022, Operating Partner at Forbion Capital Partners Management Holding BV since 2019, and Member of the International Rare Diseases Research Consortium.
Former roles include Chairman at Gotham Therapeutics Corp.
(2019–2020), Chairman at AGC Biologics SpA (2018–2020), Chairman-Supervisory Board at VectorY BV (2020–2024), Chairman at Inversago Pharma, Inc. (2020–2023), Director at The European Association for Bioindustries, Director at Quince Therapeutics SpA (2020–2023), Senior Vice President-Global Market Access at Genzyme Corp.
(1992–2018), and Chief Medical Officer & Senior Vice President at Genzyme Therapeutics Ltd. Education includes a doctorate from Università degli Studi di Modena e Reggio Emilia conferred in 1984.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/06/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Postes actifs de Carlo Incerti
| Sociétés | Poste | Début |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 02/03/2022 |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Président | 01/01/2020 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Private Equity Investor | 01/01/2019 |
Numab Therapeutics AG
 Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Directeur/Membre du Conseil | 01/05/2021 |
International Rare Diseases Research Consortium | Corporate Officer/Principal | - |
Anciens postes connus de Carlo Incerti
| Sociétés | Poste | Fin |
|---|---|---|
VectorY BV
 VectorY BV BiotechnologyHealth Technology Develops vectorized antibody treatments for people with neurodegenerative diseases | Président | 09/07/2024 |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Président | 01/01/2023 |
EryDel SpA
 EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Directeur/Membre du Conseil | 01/01/2023 |
| MOLMED S.P.A. | Président | 01/07/2020 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Carlo Incerti
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
90
Relations au 1er degré
14
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 14 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
AGC Biologics SpA
 AGC Biologics SpA Pharmaceuticals: MajorHealth Technology Provides pharmaceutical development and manufacturing services for protein-based biologics, cells & gene therapies and messenger RNA | Health Technology |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
EryDel SpA
EryDel SpA BiotechnologyHealth Technology Operates as a biotech company that develops therapeutics for the treatment of rare diseases | Health Technology |
The European Association for Bioindustries | |
Università degli Studi di Modena e Reggio Emilia
 Università degli Studi di Modena e Reggio Emilia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Numab Therapeutics AG
Numab Therapeutics AG BiotechnologyHealth Technology Develops antibody-based immunotherapies for inflammation and cancer | Health Technology |
International Rare Diseases Research Consortium | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops CB1 receptor based therapies for obesity, diabetes and complication treatment | Health Technology |
Gotham Therapeutics Corp.
 Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical medicines | Health Technology |
Dyne Therapeutics, Inc.
 Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
VectorY BV
VectorY BV BiotechnologyHealth Technology Develops vectorized antibody treatments for people with neurodegenerative diseases | Health Technology |
